Country: United States
Language: English
Source: NLM (National Library of Medicine)
FLUCYTOSINE (UNII: D83282DT06) (FLUCYTOSINE - UNII:D83282DT06)
American Health Packaging
ORAL
PRESCRIPTION DRUG
Flucytosine Capsules USP is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules USP should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules USP (See MICROBIOLOGY ). Flucytosine Capsules USP should not be used in patients with a known hypersensitivity to the drug.
Flucytosine Capsules USP, 250 mg are size 2 hard gelatin capsule with blue opaque cap and grey opaque body imprinted with "NL 771" on the cap with black ink and "250" on the body with red ink filled with white to off white powder. Unit dose packages of 30 (5 x 6) NDC 60687-352-25 Flucytosine Capsules USP, 500 mg are size 0 hard gelatin capsule with grey opaque cap and white opaque body imprinted "NL 770" on the cap with black ink and "500" on the body with red ink, filled with white to off white powder. Unit dose packages of 30 (5 x 6) NDC 60687-363-25 Store at 25°C (77°F); excursions permitted to 15°C - 30°C (59°F - 86°F). FOR YOUR PROTECTION: Do not use if blister is torn or broken.
Abbreviated New Drug Application
FLUCYTOSINE- FLUCYTOSINE CAPSULE AMERICAN HEALTH PACKAGING ---------- FLUCYTOSINE CAPSULES, USP RX ONLY 8435225/1020F WARNING USE WITH EXTREME CAUTION IN PATIENTS WITH IMPAIRED RENAL FUNCTION. CLOSE MONITORING OF HEMATOLOGIC, RENAL AND HEPATIC STATUS OF ALL PATIENTS IS ESSENTIAL. THESE INSTRUCTIONS SHOULD BE THOROUGHLY REVIEWED BEFORE ADMINISTRATION OF FLUCYTOSINE CAPSULES USP. DESCRIPTION Flucytosine Capsules USP, an antifungal agent, is available as 250 mg and 500 mg capsules for oral administration. Each capsule also contains lactose monohydrate, colloidal silicon dioxide, talc, sodium starch glycolate, magnesium stearate and hard gelatin capsule shell which contains gelatin, purified water, black iron oxide, FD&C Blue No.1, titanium dioxide and sodium lauryl sulfate for 250 mg strength; gelatin, purified water, black iron oxide and titanium dioxide for 500 mg strength. The imprinting ink contains black iron oxide, shellac, potassium hydroxide, titanium dioxide, povidone, sodium hydroxide and FD &C Red No. 40 aluminum lake for 250 mg and 500 mg strengths. Chemically, flucytosine is 5-fluorocytosine, a fluorinated pyrimidine which is related to fluorouracil and floxuridine. It is a white to off-white crystalline powder with a molecular weight of 129.09 and the following structural formula: CLINICAL PHARMACOLOGY Flucytosine is rapidly and virtually completely absorbed following oral administration. Flucytosine Capsules USP is not metabolized significantly when given orally to man. Bioavailability estimated by comparing the area under the curve of serum concentrations after oral and intravenous administration showed 78% to 89% absorption of the oral dose. Peak serum concentrations of 30 to 40 mcg/mL were reached within 2 hours of administration of a 2 g oral dose to normal subjects. Other studies revealed mean serum concentrations of approximately 70 to 80 mcg/mL 1 to 2 hours after a dose in patients with normal renal function receiving a 6-week regimen of flucytosine (150 mg/kg/day given in divided doses every 6 Read the complete document